- Home
- IRON vs NGVT Comparison
IRON vs NGVT Comparison
Compare IRON & NGVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- NGVT
- Stock Information
- Founded
- IRON 2017
- NGVT 1964
- Country
- IRON United States
- NGVT United States
- Employees
- IRON N/A
- NGVT N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- NGVT Major Chemicals
- Sector
- IRON Health Care
- NGVT Industrials
- Exchange
- IRON Nasdaq
- NGVT Nasdaq
- Market Cap
- IRON 1.4B
- NGVT 1.5B
- IPO Year
- IRON N/A
- NGVT N/A
- Fundamental
- Price
- IRON $46.68
- NGVT $41.25
- Analyst Decision
- IRON Strong Buy
- NGVT Buy
- Analyst Count
- IRON 9
- NGVT 3
- Target Price
- IRON $93.89
- NGVT $51.00
- AVG Volume (30 Days)
- IRON 354.8K
- NGVT 303.9K
- Earning Date
- IRON 05-07-2025
- NGVT 05-05-2025
- Dividend Yield
- IRON N/A
- NGVT N/A
- EPS Growth
- IRON N/A
- NGVT N/A
- EPS
- IRON N/A
- NGVT N/A
- Revenue
- IRON N/A
- NGVT $1,350,300,000.00
- Revenue This Year
- IRON N/A
- NGVT N/A
- Revenue Next Year
- IRON N/A
- NGVT $4.64
- P/E Ratio
- IRON N/A
- NGVT N/A
- Revenue Growth
- IRON N/A
- NGVT N/A
- 52 Week Low
- IRON $30.82
- NGVT $28.49
- 52 Week High
- IRON $68.73
- NGVT $51.67
- Technical
- Relative Strength Index (RSI)
- IRON 49.90
- NGVT 54.80
- Support Level
- IRON $44.85
- NGVT $40.17
- Resistance Level
- IRON $47.36
- NGVT $43.96
- Average True Range (ATR)
- IRON 2.23
- NGVT 1.25
- MACD
- IRON -0.12
- NGVT -0.08
- Stochastic Oscillator
- IRON 37.58
- NGVT 28.50
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About NGVT Ingevity Corporation
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.